Conduit Pharmaceuticals Stock Shares Owned By Institutions
| CDT Stock | 0.82 0.06 6.82% |
Conduit Pharmaceuticals fundamentals help investors to digest information that contributes to Conduit Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Conduit Stock. The fundamental analysis module provides a way to measure Conduit Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Conduit Pharmaceuticals stock.
Conduit | Shares Owned By Institutions |
Conduit Pharmaceuticals Company Shares Owned By Institutions Analysis
Conduit Pharmaceuticals' Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Current Conduit Pharmaceuticals Shares Owned By Institutions | 2.40 % |
Most of Conduit Pharmaceuticals' fundamental indicators, such as Shares Owned By Institutions, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Conduit Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Conduit Shares Owned By Institutions Driver Correlations
Understanding the fundamental principles of building solid financial models for Conduit Pharmaceuticals is extremely important. It helps to project a fair market value of Conduit Stock properly, considering its historical fundamentals such as Shares Owned By Institutions. Since Conduit Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Conduit Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Conduit Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
| Competition |
Based on the latest financial disclosure, 2.4% of Conduit Pharmaceuticals are shares owned by institutions. This is 94.62% lower than that of the Life Sciences Tools & Services sector and 94.95% lower than that of the Health Care industry. The shares owned by institutions for all United States stocks is 93.88% higher than that of the company.
Conduit Shares Owned By Institutions Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Conduit Pharmaceuticals' direct or indirect competition against its Shares Owned By Institutions to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Conduit Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Conduit Pharmaceuticals by comparing valuation metrics of similar companies.Conduit Pharmaceuticals is currently under evaluation in shares owned by institutions category among its peers.
Conduit Fundamentals
| Return On Asset | -1.09 | ||||
| Current Valuation | 7.96 M | ||||
| Shares Outstanding | 6.2 M | ||||
| Shares Owned By Insiders | 13.92 % | ||||
| Shares Owned By Institutions | 2.40 % | ||||
| Number Of Shares Shorted | 562.28 K | ||||
| Revenue | 2.46 B | ||||
| EBITDA | 266.46 M | ||||
| Net Income | 198.41 M | ||||
| Total Debt | 1.23 B | ||||
| Book Value Per Share | (9.50) X | ||||
| Cash Flow From Operations | 344.8 M | ||||
| Short Ratio | 0.51 X | ||||
| Earnings Per Share | (23.00) X | ||||
| Beta | 2.27 | ||||
| Market Capitalization | 5.09 M | ||||
| Total Asset | 3.26 B | ||||
| Retained Earnings | 1.18 B | ||||
| Working Capital | 3.93 M | ||||
| Net Asset | 3.26 B |
About Conduit Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Conduit Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Conduit Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Conduit Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Conduit Stock Analysis
When running Conduit Pharmaceuticals' price analysis, check to measure Conduit Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Conduit Pharmaceuticals is operating at the current time. Most of Conduit Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Conduit Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Conduit Pharmaceuticals' price. Additionally, you may evaluate how the addition of Conduit Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.